Sichenzia Ross Ference Carmel LLP represents Calidi Biotherapeutics, Inc. in $7.5 Million Public Offering
Press Release – New York, NY – November 14, 2024 – Sichenzia Ross Ference Carmel LLP announced that it represented Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (the “Company”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, in a public offering of 4,437,869 shares of common stock at $1.69 per share for gross proceeds of approximately $7.5 million.
The SRFC team was led by partners Jay Yamamoto, and Matthew Siracusa, associate Rohini Sud and law clerk Brady Berman.
